Progress on the Prevention and Treatment of Hantavirus Disease
- PMID: 31277410
- PMCID: PMC6669544
- DOI: 10.3390/v11070610
Progress on the Prevention and Treatment of Hantavirus Disease
Abstract
Hantaviruses, members of the order Bunyavirales, family Hantaviridae, have a world-wide distribution and are responsible for greater than 150,000 cases of disease per year. The spectrum of disease associated with hantavirus infection include hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) also known as hantavirus cardiopulmonary syndrome (HCPS). There are currently no FDA-approved vaccines or treatments for these hantavirus diseases. This review provides a summary of the status of vaccine and antiviral treatment efforts including those tested in animal models or human clinical trials.
Keywords: antiviral; hantavirus; hantavirus pulmonary syndrome; hemorrhagic fever with renal syndrome; vaccine.
Conflict of interest statement
The authors declare no conflicts of interest.
References
-
- Elliot R.M., Schmaljohn C.S. Bunyaviridae. In: Knipe D., Howley P., editors. Fields Virology. 6th ed. Volume 1. Lippincott, Williams & Wilkins; Philadelphia, PA, USA: 2013. p. 1244.
-
- Martinez-Valdebenito C., Calvo M., Vial C., Mansilla R., Marco C., Palma R.E., Vial P.A., Valdivieso F., Mertz G., Ferres M. Person-to-person household and nosocomial transmission of andes hantavirus, southern chile, 2011. Emerg. Infect. Dis. 2014;20:1629–1636. doi: 10.3201/eid2010.140353. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical